![Europe Cancer Diagnostics Market by Product (IVD [Microarray, Immunoassay, PCR, Sequencing], Imaging [CT, MRI, Mammography, Ultrasound]), Cancer Type (Breast, Lung, Colon, Prostate), and End User (Hospital, Imaging Center, Pharmaceutical) - Forecast to 2031- Product Image](http://www.researchandmarkets.com/product_images/12622/12622545_500px_jpg/europe_cancer_diagnostics_market.jpg)
The Europe cancer diagnostics market is projected to reach $12.21 billion by 2031, at a CAGR of 5.6% from 2024 to 2031.
Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report analyzes key industry drivers, restraints, challenges, and opportunities. The growth of this market is driven by the rising prevalence of cancer, supporting initiatives for early cancer diagnosis, and increasing investments and funding for cancer research. Additionally, the supporting initiatives toward precision diagnostics for cancer are expected to generate growth opportunities for the players operating in the Europe cancer diagnostics market.
However, the high cost of imaging systems restrains the growth of this market. Additionally, the lack of skilled professionals and insufficiencies in the implementation of cancer screening programs pose a significant challenge to the market's growth.
Among the products, in 2024, the IVD segment is expected to account for the largest share of the Europe cancer diagnostics market. IVD instruments provide precise, reliable screening and diagnostic testing through simple workflows and integrated software. Furthermore, IVD consumables assist healthcare providers in obtaining vital information regarding genetic abnormalities, tumor markers, and other diagnostic indicators to monitor disease development, guide treatment decisions, and assess therapy responses in cancer patients. The large market share of this segment is attributed to the advancements in IVD technology, the commercial availability of a diverse range of IVD reagents & consumables for the diagnosis of cancer, and the recurring use of IVD consumables.
Among the cancer types, in 2024, the breast cancer segment is expected to account for the largest share of the Europe cancer diagnostics market. The increase in breast cancer cases, increasing healthcare expenditure, and inclusion of certain advanced technologies such as NGS in the reimbursement have propelled the demand for cancer diagnostics for breast cancer. Additionally, government initiatives promoting breast cancer awareness regarding diagnosis and treatment boost breast cancer diagnosis. For instance, in October 2023, Galderma SA (Switzerland) launched a new breast cancer campaign called ‘Facing Breast Cancer Together’, this campaign focuses on providing support and education about breast cancer awareness. Galderma has partnered with the National Breast Cancer Foundation (NBCF) to promote breast cancer awareness.
Among the end users, in 2024, the hospitals & diagnostic laboratories segment is expected to account for the largest share of the Europe cancer diagnostics market. The large market share of this segment is attributed to the increasing cancer cases, the higher purchasing power of hospitals and diagnostic laboratories, well-equipped operating & diagnostic rooms, the presence of highly skilled healthcare professionals, ease in accessibility, better health coverage for hospital-based healthcare services from various private & group insurance plans, and the increasing number of hospitals and expansion of diagnostic laboratories.
An in-depth analysis of the Europe cancer diagnostics market provides detailed qualitative and quantitative insights into major countries, namely Germany, France, U.K., Italy, Spain, Switzerland, Netherlands, and Rest of Europe. In 2023, Germany is estimated to account for the largest share of the Europe cancer diagnostics market. The market growth in Germany is attributed to the increasing prevalence of cancer, the high adoption of advanced technologies, the established healthcare systems, rising healthcare expenditures, increasing investments and funding for cancer research, and initiatives to raise awareness about cancer diagnosis.
Some of the key players operating in the Europe Cancer Diagnostics market report are F. Hoffmann-La Roche Ltd (Switzerland), Thermo Fisher Scientific Inc. (U.S.), QIAGEN N.V. (Netherlands), Abbott Laboratories (U.S.), Illumina, Inc. (U.S.), Siemens Healthineers AG (Germany), GE HealthCare Technologies Inc. (U.S.), Koninklijke Philips N.V (Netherlands), FUJIFILM Holdings Corporation (Japan), Canon Medical Systems Corporation (a subsidiary of Canon Inc.) (Japan), and Hologic, Inc. (U.S.).
Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report analyzes key industry drivers, restraints, challenges, and opportunities. The growth of this market is driven by the rising prevalence of cancer, supporting initiatives for early cancer diagnosis, and increasing investments and funding for cancer research. Additionally, the supporting initiatives toward precision diagnostics for cancer are expected to generate growth opportunities for the players operating in the Europe cancer diagnostics market.
However, the high cost of imaging systems restrains the growth of this market. Additionally, the lack of skilled professionals and insufficiencies in the implementation of cancer screening programs pose a significant challenge to the market's growth.
Among the products, in 2024, the IVD segment is expected to account for the largest share of the Europe cancer diagnostics market. IVD instruments provide precise, reliable screening and diagnostic testing through simple workflows and integrated software. Furthermore, IVD consumables assist healthcare providers in obtaining vital information regarding genetic abnormalities, tumor markers, and other diagnostic indicators to monitor disease development, guide treatment decisions, and assess therapy responses in cancer patients. The large market share of this segment is attributed to the advancements in IVD technology, the commercial availability of a diverse range of IVD reagents & consumables for the diagnosis of cancer, and the recurring use of IVD consumables.
Among the cancer types, in 2024, the breast cancer segment is expected to account for the largest share of the Europe cancer diagnostics market. The increase in breast cancer cases, increasing healthcare expenditure, and inclusion of certain advanced technologies such as NGS in the reimbursement have propelled the demand for cancer diagnostics for breast cancer. Additionally, government initiatives promoting breast cancer awareness regarding diagnosis and treatment boost breast cancer diagnosis. For instance, in October 2023, Galderma SA (Switzerland) launched a new breast cancer campaign called ‘Facing Breast Cancer Together’, this campaign focuses on providing support and education about breast cancer awareness. Galderma has partnered with the National Breast Cancer Foundation (NBCF) to promote breast cancer awareness.
Among the end users, in 2024, the hospitals & diagnostic laboratories segment is expected to account for the largest share of the Europe cancer diagnostics market. The large market share of this segment is attributed to the increasing cancer cases, the higher purchasing power of hospitals and diagnostic laboratories, well-equipped operating & diagnostic rooms, the presence of highly skilled healthcare professionals, ease in accessibility, better health coverage for hospital-based healthcare services from various private & group insurance plans, and the increasing number of hospitals and expansion of diagnostic laboratories.
An in-depth analysis of the Europe cancer diagnostics market provides detailed qualitative and quantitative insights into major countries, namely Germany, France, U.K., Italy, Spain, Switzerland, Netherlands, and Rest of Europe. In 2023, Germany is estimated to account for the largest share of the Europe cancer diagnostics market. The market growth in Germany is attributed to the increasing prevalence of cancer, the high adoption of advanced technologies, the established healthcare systems, rising healthcare expenditures, increasing investments and funding for cancer research, and initiatives to raise awareness about cancer diagnosis.
Some of the key players operating in the Europe Cancer Diagnostics market report are F. Hoffmann-La Roche Ltd (Switzerland), Thermo Fisher Scientific Inc. (U.S.), QIAGEN N.V. (Netherlands), Abbott Laboratories (U.S.), Illumina, Inc. (U.S.), Siemens Healthineers AG (Germany), GE HealthCare Technologies Inc. (U.S.), Koninklijke Philips N.V (Netherlands), FUJIFILM Holdings Corporation (Japan), Canon Medical Systems Corporation (a subsidiary of Canon Inc.) (Japan), and Hologic, Inc. (U.S.).
Scope of the Report:
Europe Cancer Diagnostics Market Size & Trend Analysis - by Product
In Vitro Diagnostics
(Other IVD instruments include in-situ hybridization, hematology analyzers, and clinical chemistry analyzers)Diagnostic Imaging
(Other imaging instruments include Positron Emission Tomography (PET) and X-ray)- Contrast Agents
- Syringes and Injectors
- Contrast Delivery Systems
- Skin Markers
- Phantoms
- Other Imaging Consumables
- Imaging Software and Services
Europe Cancer Diagnostics Market Size & Trend Analysis - by Cancer Type
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Other Cancer Type
Europe Cancer Diagnostics Market Size & Trend Analysis - by End User
- Hospital & Diagnostics Laboratories
- Diagnostic Imaging Centers
- Pharmaceutical & Biotechnology Companies
- Academic & Research Institutes
Europe Cancer Diagnostics Market Size & Trend Analysis - by Country
- Germany
- France
- Italy
- U.K.
- Spain
- Switzerland
- Netherlands
- Rest of Europe
Table of Contents
1. Introduction
2. Research Methodology
4. Market Insights
5. Europe Cancer Diagnostics Market-by Product
6. Europe Cancer Diagnostics Market-by Cancer Type
7. Europe Cancer Diagnostics Market-by End User
8. Europe Cancer Diagnostics Market Assessment - by Geography
9. Competition Analysis
10. Company Profiles (Business Overview, Financial Overview, Product Portfolio, and Strategic Developments, SWOT Analysis)
11. Appendix
List of Tables
List of Figures
Executive Summary
The Europe cancer diagnostics market is projected to reach $12.21 billion by 2031, at a CAGR of 5.6% during the forecast period 2024-2031. The Europe cancer diagnostics market is driven by the rising prevalence of cancer, supporting initiatives for early cancer diagnosis, increasing investments and funding for cancer research, rising awareness about cancer, and advancements in cancer diagnostics technology. However, the high cost of imaging systems restrains the growth of this market.Furthermore, supporting initiatives toward precision diagnostics for cancer are expected to generate growth opportunities for the players operating in the Europe cancer diagnostics market. However, the lack of skilled professionals and insufficiencies in the national implementation of cancer screening programs are major challenges impacting the market growth.
Key Players:
The key players operating in Europe cancer diagnostics market are F. Hoffmann-La Roche Ltd (Switzerland), Thermo Fisher Scientific Inc. (U.S.), QIAGEN N.V. (Netherlands), Abbott Laboratories (U.S.), Illumina, Inc. (U.S.), Siemens Healthineers AG (Germany), GE HealthCare Technologies Inc. (U.S.), Koninklijke Philips N.V (Netherlands), FUJIFILM Holdings Corporation (Japan), Canon Medical Systems Corporation (a subsidiary of Canon Inc.) (Japan), and Hologic, Inc. (U.S.).Europe Cancer Diagnostics Market: Future Outlook
The Europe cancer diagnostics market is segmented by product (In vitro diagnostics [instruments {polymerase chain reaction (PCR), microarray, immunoassay, sequencers, and other instruments}, consumables {kits & assays and reagents}, software & services], diagnostic imaging [instruments {computed tomography (CT), magnetic resonance imaging (MRI), mammography, ultrasound, and other instruments}, consumables {syringes and injectors, contrast delivery systems, phantoms, skin markers, contrast agents, and other consumables}, software & services]), cancer type (breast cancer, lung cancer, colorectal cancer, prostate cancer, other cancer types), end user (hospitals & diagnostic laboratories, diagnostic imaging centers, pharmaceutical & biotechnology companies, academic & research institutes) and geography. The study also evaluates industry competitors and analyzes the market at country levels.Based on product, the Europe cancer diagnostics market is segmented into in vitro diagnostics (IVD) and diagnostic imaging. The IVD segment is expected to grow at the fastest CAGR during the forecast period of 2024-2031. The advancements in IVD technology, growing demand for precision oncology, the decline in genome sequencing costs, supportive initiatives for IVD in the region, and the focus of market players on new product launches are the factors driving the segment growth. For instance, In November 2023, F. Hoffmann-La Roche AG (Switzerland) launched the LightCycler PRO System, a next-generation qPCR system, to advance clinical needs in molecular diagnostic testing for cancer and infectious disease and address public health challenges.
Based on cancer type, the Europe cancer diagnostics market is segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, and other cancer types. In 2024, the breast cancer segment is expected to account for the largest share of the Europe cancer diagnostics market. The large market share of this segment is attributed to the increase in breast cancer cases, government initiatives promoting breast cancer awareness regarding diagnosis and treatment, and the increasing healthcare expenditure.
Governments and organizations are actively implementing breast cancer screenings, breast cancer awareness programs, and raising breast cancer funding to boost cancer research. For instance, In October 2023, Galderma SA (Switzerland) launched a new breast cancer campaign called ‘Facing Breast Cancer Together’, this campaign focuses on providing support and education about breast cancer awareness. Galderma has partnered with the National Breast Cancer Foundation (NBCF) to promote breast cancer awareness.
Based on end user, the Europe cancer diagnostics market is segmented into hospitals & diagnostic laboratories, diagnostics imaging centers, academic & research institutes, and pharmaceutical & biotechnology companies. In 2024, the hospitals & diagnostic laboratories segment is expected to account for the largest share of the market. The large market share of this segment is attributed to factors such as increasing cancer cases, higher purchasing power of hospitals and diagnostic laboratories, well-equipped operating & diagnostic rooms, the presence of highly skilled healthcare professionals, ease in accessibility, better health coverage for hospital-based healthcare services from various private & group insurance plans, the increasing number of hospitals and expansion of diagnostic laboratories, growing demand for precision oncology.
Precision medicine is an approach to medical treatment that considers individual differences in genes, environment, and lifestyle. Treatment with targeted cancer therapy mainly involves diagnostic testing for analyzing the biological samples, such as blood and tumor tissue, obtained from patients to identify and evaluate specific biomarkers and deliver a specific treatment accordingly. Precision diagnostics in cancer enable medical practitioners to figure out a patient's risk of developing cancers, diagnose and classify tumors, predict prognoses, select specific treatments when accessible, and track their patient's disease burden continuously.
Geographic Review:
This research report analyzes major geographies and provides a comprehensive analysis of Europe (Germany, France, U.K., Italy, Spain, Switzerland, Netherlands, and the Rest of Europe). Based on geography, in 2024, Germany is expected to account for the largest share of the Europe cancer diagnostics market. The large market share of Germany is attributed to the increased cases of genetic diseases, awareness about early genetic disease diagnosis, the government promoting certain genetic testing in case of hereditary cancers and newborn screening, and the presence of major market players.Key questions answered in the report:
- What is the current value of revenue generated by cancer diagnostic products in Europe?
- At what rate is the demand for cancer diagnostic products in Europe projected to grow for the next 5-7 years?
- What is the historical market size and growth rate for cancer diagnostic products in Europe?
- What are the major factors impacting the growth of this market at the regional level? What are the major opportunities for existing market players and new entrants in the market?
- Which segments are creating major traction for the vendors in this market in terms of product, cancer type, and end user?
- What are the key geographical trends in this market? Which countries are expected to offer significant growth opportunities for the vendors operating in the Europe cancer diagnostics market?
- Who are the major players in the Europe cancer diagnostics market? And what are their specific products offered in the cancer diagnostic industry?
- What recent developments have taken place in the Europe cancer diagnostics market, and how these strategic developments are creating an impact in this market?
Companies Mentioned
- F. Hoffmann-La Roche Ltd (Switzerland)
- Thermo Fisher Scientific Inc. (U.S.)
- QIAGEN N.V. (Netherlands)
- Abbott Laboratories (U.S.)
- Illumina Inc. (U.S.)
- Siemens Healthineers AG (Germany)
- GE HealthCare Technologies Inc. (U.S.)
- Koninklijke Philips N.V (Netherlands)
- FUJIFILM Holdings Corporation (Japan)
- Canon Medical Systems Corporation (a subsidiary of Canon Inc.) (Japan)
- Hologic Inc. (U.S.)
